We collected 97 cases of myeloid neoplasia with the rare cytogenetic event of isolated trisomy 19 (+19), with the aim to characterize this group clinically and pathologically. 51 patients with myelodysplastic syndrome (MDS +19) and 11 patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN +19) presented with +19 at disease onset and were further analyzed. Patients with insufficient data were excluded. We collected additional clinical and laboratory data and performed mutation analysis on available bone marrow biopsies. The 62 patients of both disease groups turned out to be remarkably homogeneous in terms of male sex (85%), the presence of anemia with increased numbers of ring sideroblasts (RS, 80%), the absence of an SF3B1 mutation (95%), and the overall rather consistent presence of SRSF2 (61%) or ASXL1 (39%) mutations. MDS +19 patients with available follow-up (1 month to 7.5 years) presented or progressed with significant fibrosis (45%), leuko- or monocytosis (13%) or acute leukemia (28%). Compared to a control cohort of 23 patients with MDS and an SRSF2 mutation, but without isolated +19 (MDS-SRSF2), the 16 MDS +19 patients with SRSF2 mutation and the 12 MDS +19 patients with an ASXL1 mutation showed a striking difference in the presence of ≥ 15% RS (73% and 67% versus 17% in MDS-SRSF2) and the occurrence of fibrosis (44% and 57% versus 4% in MDS-SRSF2). Although all individual features observed in the MDS +19 and MDS/MPN +19 cohorts are seen in MDS and MDS/MPN in general, their combination is rather unique and provides clues regarding disease evolution in this rare, cytogenetically defined group of myeloid neoplasia.

Biopticka Laborator Pilsen Czech Republic

Department of Biology and Medical Genetics 2nd Faculty of Medicine University Hospital Motol Prague Czech Republic

Department of Human Genetics Radboud University Medical Center Nijmegen Netherlands

Department of Pathology Medical Faculty Charles University Pilsen Czech Republic

Department of Pathology Radboud University Medical Center Nijmegen Netherlands

Institute of Hematology and Blood Transfusion MDS Registry Prague Czech Republic

Internal Medicine Meander Medisch Centrum Amersfoort Netherlands

Laboratory Hematology Department of Laboratory Medicine Radboud University Medical Center Nijmegen Netherlands

Munich Leukemia Laboratory Munich Germany

Zobrazit více v PubMed

Johansson B, Billström R, Mauritzson N, Mitelman F (1994) Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet Cytogenet 74(1):62–65. 10.1016/0165-4608(94)90031-0 PubMed

Espersen ADL, Noren-Nyström U, Abrahamsson J, Ha SY, Pronk CJ. Jahnukainen K et al (2018) AML with t (7; 12)(q36; p13) is associated with infancy and trisomy 19. Data from NOPHO-AML and review of the literature. Genes, Chromosomes & Cancer, 57(7): 359–365. 10.1002/gcc.22538 PubMed

Kayser S, Martínez-Cuadrón D, Rodriguez-Veiga R, Hänel M, Tormo M, Schäfer-Eckart K et al (2023) Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia. Haematologica 108(8):2059–2066. 10.3324/haematol.2022.282127 PubMed PMC

Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC (2001) Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. Genes Chromosomes Cancer 32(3):285–293. 10.1002/gcc.1192 PubMed

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30(8):820–829. 10.1200/JCO.2011.35.6394 PubMed PMC

Daskalakis M, Mauritzson N, Johansson B, Bouabdallah K, Onida F, Kunzmann R et al (2006) Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia. Leuk Res 30(8):1043–1047. 10.1016/j.leukres.2006.01.003 PubMed

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365. 10.1182/blood-2009-11-254441 PubMed

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465. 10.1182/blood-2012-03-420489 PubMed PMC

van Zeventer IA, de Graaf AO, Salzbrunn JB, Nolte IM, Kamphuis P, Dinmohamed A et al (2023) Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population. Cancer Cell 41(6):1017-1031.e4. 10.1016/j.ccell.2023.04.006 PubMed

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36:1703–1719. 10.1038/s41375-022-01613-1 PubMed PMC

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228. 10.1182/blood.2022015850 PubMed PMC

Malcovati L, Porta MGD, Pascutto C, Invernizzi R, Boni M, Travaglino E et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23(30):7594–7603. 10.1200/JCO.2005.01.7038 PubMed

Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Summerer I et al (2023) Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts. Leukemia 37:500–502. 10.1038/s41375-022-01783-y PubMed PMC

Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF et al (2012) The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 120(15):3106–3111. 10.1182/blood-2012-02-412296 PubMed

Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J et al (2023) Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37:1397–1400. 10.1038/s41375-023-01899-9 PubMed

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122(22):3616–3627. 10.1182/blood-2013-08-518886 PubMed PMC

Germing U, Gattermann N, Strupp C, Aivado M et al (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24(12):983–992. 10.1016/s0145-2126(00)00088-6 PubMed

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C et al (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118(24):6239–6246. 10.1182/blood-2011-09-377275 PubMed PMC

Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C et al (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27(5):754–762. 10.1200/JCO.2008.18.2246 PubMed

Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110(13):4385–4395. 10.1182/blood-2007-03-082404 PubMed

Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N et al (2017) New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res 57:78–84. 10.1016/j.leukres.2017.02.008 PubMed

Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf AO, Smith A et al (2025) Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes. HemaSphere 9(1):e70073. 10.1002/hem3.70073 PubMed PMC

Jiang L, Wang L, Shen C, Zhu S, Lang W, Luo Y et al (2022) Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes. J Cancer Res Clin Oncol. 10.1007/s00432-021-03905-y PubMed PMC

Duncavage EJ, Schroeder MC, O’Laughlin M, Wilson R, MacMillan S, Bohannon A, Kruchowski S et al (2021) Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med 384(10):924–935. 10.1056/NEJMoa2024534 PubMed PMC

Kolquist KA, Schultz RA, Furrow A, Brown TC, Han JY, Campbell LJ et al (2011) Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Cancer Genet 204(11):603–628 PubMed

Musilova J, Michalova K (1988) Chromosome study of 85 patients with myelodysplastic syndrome. Cancer Genet Cytogenet 33(1):39–50. 10.1016/0165-4608(88)90048-9 PubMed

Wang SA, Galili N, Cerny J, Sechman E, Chen SS, Loew J et al (2006) Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol 126(5):789–797. 10.1309/FU04-P779-U310-R3EE PubMed

Mansoor AM, Bharadwaj TP, Sethuraman S, Chandy M, Pushpa V, Kamada N, Murthy PB (1993) Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients. Cancer Genet Cytogenet 65(1):12–20. 10.1016/0165-4608(93)90052-n PubMed

Knuutila S, Teerenhovi L, Borgström GH (1984) Chromosome instability is associated with hypodiploid clones in myelodysplastic syndromes. Hereditas 101(1):19–30. 10.1111/j.1601-5223.1984.tb00444.x PubMed

Solé F, Prieto F, Badia L, Woessner S, Florensa L, Caballin MR et al (1992) Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 64(1):12–20. 10.1016/0165-4608(92)90315-y PubMed

Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, Wang SA (2008) Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 113(12):3331–3340. 10.1002/cncr.23977 PubMed

Werner M, Maschek H, Kaloutsi V, Choritz H, Georgii A (1992) Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance. Virchows Arch 421(1):47–52. 10.1007/BF01607138 PubMed

Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A et al (2012) Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 5:4. 10.1186/1756-8722-5-4 PubMed PMC

Humphries JE, Wheby MS (1990) Trisomy 19 in a patient with myelodysplastic syndrome and thrombocytosis. Cancer Genet Cytogenet 44(2):187–191. 10.1016/0165-4608(90)90045-c PubMed

Jung SI, Cho HS, Lee CH, Kim KD, Ha JO, Kim MK et al (2008) Two cases of trisomy 19 as a sole chromosomal abnormality in myeloid disorders. Korean J Lab Med 28(3):174–178. 10.3343/kjlm.2008.28.3.174 PubMed

United Kingdom Cancer Cytogenetics Group (UKCCG) (1992) Primary, single, autosomal trisomies associated with haematological disorders. Leuk Res 16(9):841–851. 10.1016/0145-2126(92)90030-B PubMed

van Lom K, Hagemeijer A, Vandekerckhove F, Smit EM, Löwenberg B (1996) Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 93(3):594–600. 10.1046/j.1365-2141.1996.d01-1692.x PubMed

Muhyieddeen K, Natelson EA (2012) Atypical ringed sideroblasts in association with trisomy 19 and myelodysplasia. Comp Clin Pathol 21:223–225. 10.1007/s00580-011-1298-0

Rashid A, Khurshid M, Shaikh U, Adil S (2014) Chromosomal abnormalities in primary myelodysplastic syndrome. JCPSP J Coll Physicians Surg Pak 24(9):632 PubMed

Kardon N, Schulman P, Degnan TJ, Budman DR, Davis J, Vinciguerra V (1982) Cytogenetic findings in the dysmyelopoietic syndrome. Cancer 50(12):2834–2838. 10.1002/1097-0142(19821215)50:12%3c2834::aid-cncr2820501224%3e3.0.co;2-h PubMed

Palomo L, Meggendorfer M, Hutter S, Twardziok S, Ademà V, Fuhrmann I et al (2020) Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood 136(16):1851–1862. 10.1182/blood.2019004229 PubMed PMC

Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A et al (2022) Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J 12(2):26. 10.1038/s41408-022-00622-8 PubMed PMC

Todisco G, Creignou M, Bernard E, Björklund AC, Moura PL, Tesi B et al (2023) Integrated genomic and transcriptomic analysis improves disease classification and risk stratification of MDS with ring sideroblasts. Clin Cancer Res 29(20):4256–4267. 10.1158/1078-0432.CCR-23-0538 PubMed PMC

Maggioni G, Travaglino E, Pierola AA, Kaivers J, Arnan M, Meggendorfer M et al (2020) A sex-informed approach to improve prognostication and personalized decision-making process in myelodysplastic syndromes. A European study of 11.878 patients. Blood 136:23–24. 10.1016/S2352-3026(22)00323-4

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M et al (2015) SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126(2):233–241. 10.1182/blood-2015-03-633537 PubMed PMC

Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al (2012) SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119(2):569–572. 10.1182/blood-2011-09-377994 PubMed PMC

Mortuza S, Chin-Yee B, James TE, Chin-Yee IH, Hedley BD, Ho JM et al (2024) Myelodysplastic neoplasms (MDS) with ring sideroblasts or PubMed PMC

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365(15):1384–1395. 10.1056/NEJMoa1103283 PubMed PMC

Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G et al (2021) Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol 43(3):426–432. 10.1111/ijlh.13400 PubMed PMC

Jain AG, Zhang L, Bennett JM, Komrokji R (2022) Myelodysplastic syndromes with bone marrow fibrosis: an update. Ann Lab Med 42:299–305. 10.3343/alm.2022.42.3.299 PubMed PMC

Stelling A, Jonas BA, Rashidi HH, Abedi M, Chen M (2015) Acute myeloid leukemia with isolated trisomy 19 associated with diffuse myelofibrosis and osteosclerosis. Cancers (Basel) 7(4):2459–2465. 10.3390/cancers7040903 PubMed PMC

Länger F, Dingemann J, Kreipe H, Lehmann U (2005) Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 29(3):325–329. 10.1016/j.leukres.2004.08.004 PubMed

Rodriguez-Sevilla JJ, Calvo X, Arenillas L (2022) Causes and pathophysiology of acquired sideroblastic anemia. Genes 13(9):1562. 10.3390/genes13091562 PubMed PMC